Baumann Frederic, Peña Constantino, Kloeckner Roman, Katzen Barry T, Gandhi Ripal, Benenati James B
1 Miami Cardiac & Vascular Institute, Baptist Hospital, Miami, FL, USA.
2 Clinical and Interventional Angiology, University Hospital of Zurich, Zurich, Switzerland.
Vasc Endovascular Surg. 2017 May;51(4):183-187. doi: 10.1177/1538574417698903. Epub 2017 Mar 20.
To evaluate the impact of a new angiographic imaging technology on radiation dose during visceral embolization procedures involving both fluoroscopy and digital subtraction angiography.
A retrospective analysis from a single-center consecutive series of patients was performed comparing 2 angiographic imaging systems. The AlluraClarity (CIQ; Philips Healthcare, Best, the Netherlands) was used in 100 patients (n = 59 male, mean age: 70.6 years) from July 2013 to April 2014 and compared to the former AlluraXper (AX) technology used in 139 patients (n = 71 male, mean age: 70.1 years) from May 2011 to June 2013. Patients were categorized according to body mass index (BMI [kg/m])-group 1: BMI <25, group 2: BMI ≥25 and <30, and group 3: BMI ≥30. Fluoroscopy time, the total dose of iodinated contrast administered, and procedural AirKerma (Ka, r [mGy]) were obtained.
Mean BMI was 26.4 ± 5.0 kg/m in the CIQ and 26.4 ± 7.1 kg/m in the AX group ( P = .93). Fluoroscopy time and the amount of contrast media were equally distributed. Ka, r was 1342.9 mGy versus 2214.8 mGy ( P < .001, t test) when comparing CIQ to AX. Comparing CIQ to AX, BMI subgroup analysis revealed a mean Ka, r of 970.1 to 1586.1 mGy ( P = .003, t test), 1484.7 to 2170.1 mGy ( P = .02, t test), and 1848.8 to 3348.9 mGy ( P = .001, t test) in BMI groups 1, 2, and 3, respectively.
The CIQ technology significantly reduced mean radiation dose by 39.4% for visceral embolization procedures when compared to fluoroscopy time and contrast media dose. This dose relationship was consistent across all BMI groups.
评估一种新的血管造影成像技术对涉及透视和数字减影血管造影的内脏栓塞手术中辐射剂量的影响。
对单中心连续系列患者进行回顾性分析，比较两种血管造影成像系统。2013年7月至2014年4月，100例患者（n = 59例男性，平均年龄：70.6岁）使用了AlluraClarity（CIQ；飞利浦医疗保健公司，荷兰贝斯特），并与2011年5月至2013年6月使用前一种AlluraXper（AX）技术的139例患者（n = 71例男性，平均年龄：70.1岁）进行比较。根据体重指数（BMI [kg/m]）对患者进行分类——第1组：BMI <25，第2组：BMI≥25且<30，第3组：BMI≥30。获取透视时间、碘化造影剂的总给药剂量和手术空气比释动能（Ka，r [mGy]）。
CIQ组的平均BMI为26.4±5.0 kg/m，AX组为26.4±7.1 kg/m（P = 0.93）。透视时间和造影剂用量分布均匀。将CIQ与AX比较时，Ka，r分别为1342.9 mGy和2214.8 mGy（P < 0.001，t检验）。将CIQ与AX比较时，BMI亚组分析显示，第1、2和3组BMI的平均Ka，r分别为970.1至1586.1 mGy（P = 0.003，t检验）、1484.7至2170.1 mGy（P = 0.02，t检验）和1848.8至3348.9 mGy（P = 0.001，t检验）。
与透视时间和造影剂剂量相比，CIQ技术在内脏栓塞手术中显著降低了平均辐射剂量39.4%。这种剂量关系在所有BMI组中都是一致的。
